•
Jun 30, 2022

Glaukos Q2 2022 Earnings Report

Glaukos reported a decrease in net sales but an increase in gross margin and non-GAAP gross margin compared to the same quarter last year. The company is focused on launching new products and advancing its pipeline of novel platform technologies.

Key Takeaways

Glaukos Corporation announced its second quarter 2022 financial results, with net sales of $72.7 million. The company's gross margin was approximately 75%, and non-GAAP gross margin was approximately 83%. Glaukos raised its 2022 net sales guidance to $275 million to $280 million.

Net sales reached $72.7 million.

Glaucoma net sales were $56.1 million.

Corneal Health net sales totaled $16.6 million.

Gross margin was approximately 75%, while non-GAAP gross margin was approximately 83%.

Total Revenue
$72.7M
Previous year: $78.1M
-6.9%
EPS
-$0.83
Previous year: -$0.11
+654.5%
Gross margin
75%
Previous year: 77%
-2.6%
Non-GAAP gross margin
83%
Previous year: 84%
-1.2%
SG&A expenses
$49.9M
Previous year: $45.3M
+10.2%
Gross Profit
$54.9M
Previous year: $60.3M
-9.1%
Cash and Equivalents
$103M
Previous year: $118M
-13.3%
Free Cash Flow
-$21.6M
Previous year: -$3.97M
+444.4%
Total Assets
$1.03B
Previous year: $1.04B
-1.2%

Glaukos

Glaukos

Glaukos Revenue by Segment

Forward Guidance

The company expects 2022 net sales to be in the range of $275 million to $280 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income